Low-dose decitabine as part of a modified Bu-Cy conditioning regimen improves survival in AML patients with active disease undergoing allogeneic hematopoietic stem cell transplantation
Relapse is the major cause of mortality in patients with acute myeloid leukemia (AML) after allogeneic hematopoietic stem cell transplantation (allo-HSCT). Effective preventive intervention in high-risk AML may be crucial. In this study, we investigated the clinical efficacy and safety of low dose d...
Gespeichert in:
| Veröffentlicht in: | Bone marrow transplantation (Basingstoke) 2021-07, Vol.56 (7), p.1674-1682 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 1682 |
|---|---|
| container_issue | 7 |
| container_start_page | 1674 |
| container_title | Bone marrow transplantation (Basingstoke) |
| container_volume | 56 |
| creator | Tang, Xiaowen Valdez, Benigno C. Ma, Yunju Zhang, Qianqian Qu, Changju Dai, Haiping Yin, Jia Li, Zheng Xu, Ting Xu, Yang Chen, Jia Zhu, Xiaming Chen, Zixing Wu, Depei Andersson, Borje S. |
| description | Relapse is the major cause of mortality in patients with acute myeloid leukemia (AML) after allogeneic hematopoietic stem cell transplantation (allo-HSCT). Effective preventive intervention in high-risk AML may be crucial. In this study, we investigated the clinical efficacy and safety of low dose decitabine (DAC) as part of a modified Busulfan-Cyclophosphamide (Bu-Cy) regimen for high-risk AML patients undergoing allo-HSCT to reduce relapse rate. Fifty-nine patients received DAC (20 mg/m
2
/d, i.v.) for 5 days, followed by modified Bu-Cy (DAC group). A matched-pair control (CON) group of 177 patients (matched 1:3) received modified Bu-Cy only. The differences were more substantial among patients with active disease: 2-year OS, 80.7% (DAC) versus 43.5% (CON),
P
= 0.011 and 2-year LFS, 64.9% (DAC) versus 39.2% (CON),
P
= 0.024. Median time to relapse was 8 months (DAC) versus 5 months (CON) for the entire groups and 6.5 months (DAC) versus 3.5 months (CON) for patients with active disease. In summary, our data indicated that the conditioning regimen containing low dose DAC may confer a survival advantage in high-risk AML patients with active disease undergoing allo-HSCT, and a prospective randomized trial is warranted to confirm these observations. |
| doi_str_mv | 10.1038/s41409-021-01238-5 |
| format | Article |
| fullrecord | <record><control><sourceid>gale_proqu</sourceid><recordid>TN_cdi_proquest_miscellaneous_2494304246</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A667741620</galeid><sourcerecordid>A667741620</sourcerecordid><originalsourceid>FETCH-LOGICAL-c473t-120b10a0f0f7c050b4ceaeaee836c5a106546ce23c735d9e5d9be27dcd3dc4243</originalsourceid><addsrcrecordid>eNp9ktuKFDEQhhtR3HH1BbyQgCDe9JpTny5nB08w4o1eh0xS3VNLdzIm6Vn2zXw8087quiISQkjy1V9VyV8Uzxm9YFS0b6JkknYl5aykjIu2rB4UKyabuqxEXT0sVpTXbSlE3Z0VT2K8opRJSavHxVk-E03b8lXxfeuvS-sjEAsGk96hA6IjOeiQiO-JJpO32CNYcjmXmxtivLOY0Dt0Awkw4ASO4HQI_giRxDkc8ahHgo6sP22zTEJwKZJrTHuiTcJjzoQRdM44Owth8IuQHkc_gAM0ZA-TTv7gEVLexQQTMTCOJAXt4mHULukl_dPiUa_HCM9u1_Pi67u3XzYfyu3n9x83621pZCNSyTjdMappT_vG0IrupAGdB7SiNpVmtK5kbYAL04jKdpDnDnhjjRXWSC7FefH6pJs7_DZDTGrCuBSkHfg5Ki47KWgm64y-_Au98nNwuTrFK9nlP2o7fkcNegSFrve5M7OIqnVdN41kNaeZuvgHlYeFCfMfQI_5_F7Aqz8C9qDHtI9-nJe3ivdBfgJN8DEG6NUh4KTDjWJULb5SJ1-p7Cv101eqykEvblubdxPY3yG_jJQBcQJivnIDhLve_yP7A_pu2lc</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2549012892</pqid></control><display><type>article</type><title>Low-dose decitabine as part of a modified Bu-Cy conditioning regimen improves survival in AML patients with active disease undergoing allogeneic hematopoietic stem cell transplantation</title><source>MEDLINE</source><source>SpringerLink Journals</source><source>EZB-FREE-00999 freely available EZB journals</source><creator>Tang, Xiaowen ; Valdez, Benigno C. ; Ma, Yunju ; Zhang, Qianqian ; Qu, Changju ; Dai, Haiping ; Yin, Jia ; Li, Zheng ; Xu, Ting ; Xu, Yang ; Chen, Jia ; Zhu, Xiaming ; Chen, Zixing ; Wu, Depei ; Andersson, Borje S.</creator><creatorcontrib>Tang, Xiaowen ; Valdez, Benigno C. ; Ma, Yunju ; Zhang, Qianqian ; Qu, Changju ; Dai, Haiping ; Yin, Jia ; Li, Zheng ; Xu, Ting ; Xu, Yang ; Chen, Jia ; Zhu, Xiaming ; Chen, Zixing ; Wu, Depei ; Andersson, Borje S.</creatorcontrib><description>Relapse is the major cause of mortality in patients with acute myeloid leukemia (AML) after allogeneic hematopoietic stem cell transplantation (allo-HSCT). Effective preventive intervention in high-risk AML may be crucial. In this study, we investigated the clinical efficacy and safety of low dose decitabine (DAC) as part of a modified Busulfan-Cyclophosphamide (Bu-Cy) regimen for high-risk AML patients undergoing allo-HSCT to reduce relapse rate. Fifty-nine patients received DAC (20 mg/m
2
/d, i.v.) for 5 days, followed by modified Bu-Cy (DAC group). A matched-pair control (CON) group of 177 patients (matched 1:3) received modified Bu-Cy only. The differences were more substantial among patients with active disease: 2-year OS, 80.7% (DAC) versus 43.5% (CON),
P
= 0.011 and 2-year LFS, 64.9% (DAC) versus 39.2% (CON),
P
= 0.024. Median time to relapse was 8 months (DAC) versus 5 months (CON) for the entire groups and 6.5 months (DAC) versus 3.5 months (CON) for patients with active disease. In summary, our data indicated that the conditioning regimen containing low dose DAC may confer a survival advantage in high-risk AML patients with active disease undergoing allo-HSCT, and a prospective randomized trial is warranted to confirm these observations.</description><identifier>ISSN: 0268-3369</identifier><identifier>EISSN: 1476-5365</identifier><identifier>DOI: 10.1038/s41409-021-01238-5</identifier><identifier>PMID: 33637882</identifier><language>eng</language><publisher>London: Nature Publishing Group UK</publisher><subject>5-aza-2'-deoxycytidine ; 692/699/1541/1990/283/1897 ; 692/699/67/1990/283/1897 ; Acute myeloid leukemia ; Busulfan ; Cell Biology ; Conditioning ; Cyclophosphamide ; Decitabine ; Dosage and administration ; Graft vs Host Disease ; Hematology ; Hematopoietic Stem Cell Transplantation ; Hematopoietic stem cells ; Humans ; Internal Medicine ; Leukemia ; Leukemia, Myeloid, Acute - therapy ; Medicine ; Medicine & Public Health ; Myeloid leukemia ; Prospective Studies ; Public Health ; Retrospective Studies ; Risk ; Stem cell transplantation ; Stem Cells ; Survival ; Transplantation ; Transplantation Conditioning</subject><ispartof>Bone marrow transplantation (Basingstoke), 2021-07, Vol.56 (7), p.1674-1682</ispartof><rights>The Author(s), under exclusive licence to Springer Nature Limited part of Springer Nature 2021</rights><rights>COPYRIGHT 2021 Nature Publishing Group</rights><rights>The Author(s), under exclusive licence to Springer Nature Limited part of Springer Nature 2021.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c473t-120b10a0f0f7c050b4ceaeaee836c5a106546ce23c735d9e5d9be27dcd3dc4243</citedby><cites>FETCH-LOGICAL-c473t-120b10a0f0f7c050b4ceaeaee836c5a106546ce23c735d9e5d9be27dcd3dc4243</cites><orcidid>0000-0003-1766-7891</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://link.springer.com/content/pdf/10.1038/s41409-021-01238-5$$EPDF$$P50$$Gspringer$$H</linktopdf><linktohtml>$$Uhttps://link.springer.com/10.1038/s41409-021-01238-5$$EHTML$$P50$$Gspringer$$H</linktohtml><link.rule.ids>314,776,780,27901,27902,41464,42533,51294</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/33637882$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Tang, Xiaowen</creatorcontrib><creatorcontrib>Valdez, Benigno C.</creatorcontrib><creatorcontrib>Ma, Yunju</creatorcontrib><creatorcontrib>Zhang, Qianqian</creatorcontrib><creatorcontrib>Qu, Changju</creatorcontrib><creatorcontrib>Dai, Haiping</creatorcontrib><creatorcontrib>Yin, Jia</creatorcontrib><creatorcontrib>Li, Zheng</creatorcontrib><creatorcontrib>Xu, Ting</creatorcontrib><creatorcontrib>Xu, Yang</creatorcontrib><creatorcontrib>Chen, Jia</creatorcontrib><creatorcontrib>Zhu, Xiaming</creatorcontrib><creatorcontrib>Chen, Zixing</creatorcontrib><creatorcontrib>Wu, Depei</creatorcontrib><creatorcontrib>Andersson, Borje S.</creatorcontrib><title>Low-dose decitabine as part of a modified Bu-Cy conditioning regimen improves survival in AML patients with active disease undergoing allogeneic hematopoietic stem cell transplantation</title><title>Bone marrow transplantation (Basingstoke)</title><addtitle>Bone Marrow Transplant</addtitle><addtitle>Bone Marrow Transplant</addtitle><description>Relapse is the major cause of mortality in patients with acute myeloid leukemia (AML) after allogeneic hematopoietic stem cell transplantation (allo-HSCT). Effective preventive intervention in high-risk AML may be crucial. In this study, we investigated the clinical efficacy and safety of low dose decitabine (DAC) as part of a modified Busulfan-Cyclophosphamide (Bu-Cy) regimen for high-risk AML patients undergoing allo-HSCT to reduce relapse rate. Fifty-nine patients received DAC (20 mg/m
2
/d, i.v.) for 5 days, followed by modified Bu-Cy (DAC group). A matched-pair control (CON) group of 177 patients (matched 1:3) received modified Bu-Cy only. The differences were more substantial among patients with active disease: 2-year OS, 80.7% (DAC) versus 43.5% (CON),
P
= 0.011 and 2-year LFS, 64.9% (DAC) versus 39.2% (CON),
P
= 0.024. Median time to relapse was 8 months (DAC) versus 5 months (CON) for the entire groups and 6.5 months (DAC) versus 3.5 months (CON) for patients with active disease. In summary, our data indicated that the conditioning regimen containing low dose DAC may confer a survival advantage in high-risk AML patients with active disease undergoing allo-HSCT, and a prospective randomized trial is warranted to confirm these observations.</description><subject>5-aza-2'-deoxycytidine</subject><subject>692/699/1541/1990/283/1897</subject><subject>692/699/67/1990/283/1897</subject><subject>Acute myeloid leukemia</subject><subject>Busulfan</subject><subject>Cell Biology</subject><subject>Conditioning</subject><subject>Cyclophosphamide</subject><subject>Decitabine</subject><subject>Dosage and administration</subject><subject>Graft vs Host Disease</subject><subject>Hematology</subject><subject>Hematopoietic Stem Cell Transplantation</subject><subject>Hematopoietic stem cells</subject><subject>Humans</subject><subject>Internal Medicine</subject><subject>Leukemia</subject><subject>Leukemia, Myeloid, Acute - therapy</subject><subject>Medicine</subject><subject>Medicine & Public Health</subject><subject>Myeloid leukemia</subject><subject>Prospective Studies</subject><subject>Public Health</subject><subject>Retrospective Studies</subject><subject>Risk</subject><subject>Stem cell transplantation</subject><subject>Stem Cells</subject><subject>Survival</subject><subject>Transplantation</subject><subject>Transplantation Conditioning</subject><issn>0268-3369</issn><issn>1476-5365</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2021</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>BENPR</sourceid><recordid>eNp9ktuKFDEQhhtR3HH1BbyQgCDe9JpTny5nB08w4o1eh0xS3VNLdzIm6Vn2zXw8087quiISQkjy1V9VyV8Uzxm9YFS0b6JkknYl5aykjIu2rB4UKyabuqxEXT0sVpTXbSlE3Z0VT2K8opRJSavHxVk-E03b8lXxfeuvS-sjEAsGk96hA6IjOeiQiO-JJpO32CNYcjmXmxtivLOY0Dt0Awkw4ASO4HQI_giRxDkc8ahHgo6sP22zTEJwKZJrTHuiTcJjzoQRdM44Owth8IuQHkc_gAM0ZA-TTv7gEVLexQQTMTCOJAXt4mHULukl_dPiUa_HCM9u1_Pi67u3XzYfyu3n9x83621pZCNSyTjdMappT_vG0IrupAGdB7SiNpVmtK5kbYAL04jKdpDnDnhjjRXWSC7FefH6pJs7_DZDTGrCuBSkHfg5Ki47KWgm64y-_Au98nNwuTrFK9nlP2o7fkcNegSFrve5M7OIqnVdN41kNaeZuvgHlYeFCfMfQI_5_F7Aqz8C9qDHtI9-nJe3ivdBfgJN8DEG6NUh4KTDjWJULb5SJ1-p7Cv101eqykEvblubdxPY3yG_jJQBcQJivnIDhLve_yP7A_pu2lc</recordid><startdate>20210701</startdate><enddate>20210701</enddate><creator>Tang, Xiaowen</creator><creator>Valdez, Benigno C.</creator><creator>Ma, Yunju</creator><creator>Zhang, Qianqian</creator><creator>Qu, Changju</creator><creator>Dai, Haiping</creator><creator>Yin, Jia</creator><creator>Li, Zheng</creator><creator>Xu, Ting</creator><creator>Xu, Yang</creator><creator>Chen, Jia</creator><creator>Zhu, Xiaming</creator><creator>Chen, Zixing</creator><creator>Wu, Depei</creator><creator>Andersson, Borje S.</creator><general>Nature Publishing Group UK</general><general>Nature Publishing Group</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7QO</scope><scope>7QP</scope><scope>7T5</scope><scope>7U9</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8FD</scope><scope>8FE</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FR3</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>H94</scope><scope>HCIFZ</scope><scope>K9.</scope><scope>LK8</scope><scope>M0S</scope><scope>M1P</scope><scope>M7N</scope><scope>M7P</scope><scope>P64</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0003-1766-7891</orcidid></search><sort><creationdate>20210701</creationdate><title>Low-dose decitabine as part of a modified Bu-Cy conditioning regimen improves survival in AML patients with active disease undergoing allogeneic hematopoietic stem cell transplantation</title><author>Tang, Xiaowen ; Valdez, Benigno C. ; Ma, Yunju ; Zhang, Qianqian ; Qu, Changju ; Dai, Haiping ; Yin, Jia ; Li, Zheng ; Xu, Ting ; Xu, Yang ; Chen, Jia ; Zhu, Xiaming ; Chen, Zixing ; Wu, Depei ; Andersson, Borje S.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c473t-120b10a0f0f7c050b4ceaeaee836c5a106546ce23c735d9e5d9be27dcd3dc4243</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2021</creationdate><topic>5-aza-2'-deoxycytidine</topic><topic>692/699/1541/1990/283/1897</topic><topic>692/699/67/1990/283/1897</topic><topic>Acute myeloid leukemia</topic><topic>Busulfan</topic><topic>Cell Biology</topic><topic>Conditioning</topic><topic>Cyclophosphamide</topic><topic>Decitabine</topic><topic>Dosage and administration</topic><topic>Graft vs Host Disease</topic><topic>Hematology</topic><topic>Hematopoietic Stem Cell Transplantation</topic><topic>Hematopoietic stem cells</topic><topic>Humans</topic><topic>Internal Medicine</topic><topic>Leukemia</topic><topic>Leukemia, Myeloid, Acute - therapy</topic><topic>Medicine</topic><topic>Medicine & Public Health</topic><topic>Myeloid leukemia</topic><topic>Prospective Studies</topic><topic>Public Health</topic><topic>Retrospective Studies</topic><topic>Risk</topic><topic>Stem cell transplantation</topic><topic>Stem Cells</topic><topic>Survival</topic><topic>Transplantation</topic><topic>Transplantation Conditioning</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Tang, Xiaowen</creatorcontrib><creatorcontrib>Valdez, Benigno C.</creatorcontrib><creatorcontrib>Ma, Yunju</creatorcontrib><creatorcontrib>Zhang, Qianqian</creatorcontrib><creatorcontrib>Qu, Changju</creatorcontrib><creatorcontrib>Dai, Haiping</creatorcontrib><creatorcontrib>Yin, Jia</creatorcontrib><creatorcontrib>Li, Zheng</creatorcontrib><creatorcontrib>Xu, Ting</creatorcontrib><creatorcontrib>Xu, Yang</creatorcontrib><creatorcontrib>Chen, Jia</creatorcontrib><creatorcontrib>Zhu, Xiaming</creatorcontrib><creatorcontrib>Chen, Zixing</creatorcontrib><creatorcontrib>Wu, Depei</creatorcontrib><creatorcontrib>Andersson, Borje S.</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Biotechnology Research Abstracts</collection><collection>Calcium & Calcified Tissue Abstracts</collection><collection>Immunology Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Technology Research Database</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>Natural Science Collection (ProQuest)</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Engineering Research Database</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>ProQuest Biological Science Collection</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Algology Mycology and Protozoology Abstracts (Microbiology C)</collection><collection>Biological Science Database</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>MEDLINE - Academic</collection><jtitle>Bone marrow transplantation (Basingstoke)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Tang, Xiaowen</au><au>Valdez, Benigno C.</au><au>Ma, Yunju</au><au>Zhang, Qianqian</au><au>Qu, Changju</au><au>Dai, Haiping</au><au>Yin, Jia</au><au>Li, Zheng</au><au>Xu, Ting</au><au>Xu, Yang</au><au>Chen, Jia</au><au>Zhu, Xiaming</au><au>Chen, Zixing</au><au>Wu, Depei</au><au>Andersson, Borje S.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Low-dose decitabine as part of a modified Bu-Cy conditioning regimen improves survival in AML patients with active disease undergoing allogeneic hematopoietic stem cell transplantation</atitle><jtitle>Bone marrow transplantation (Basingstoke)</jtitle><stitle>Bone Marrow Transplant</stitle><addtitle>Bone Marrow Transplant</addtitle><date>2021-07-01</date><risdate>2021</risdate><volume>56</volume><issue>7</issue><spage>1674</spage><epage>1682</epage><pages>1674-1682</pages><issn>0268-3369</issn><eissn>1476-5365</eissn><abstract>Relapse is the major cause of mortality in patients with acute myeloid leukemia (AML) after allogeneic hematopoietic stem cell transplantation (allo-HSCT). Effective preventive intervention in high-risk AML may be crucial. In this study, we investigated the clinical efficacy and safety of low dose decitabine (DAC) as part of a modified Busulfan-Cyclophosphamide (Bu-Cy) regimen for high-risk AML patients undergoing allo-HSCT to reduce relapse rate. Fifty-nine patients received DAC (20 mg/m
2
/d, i.v.) for 5 days, followed by modified Bu-Cy (DAC group). A matched-pair control (CON) group of 177 patients (matched 1:3) received modified Bu-Cy only. The differences were more substantial among patients with active disease: 2-year OS, 80.7% (DAC) versus 43.5% (CON),
P
= 0.011 and 2-year LFS, 64.9% (DAC) versus 39.2% (CON),
P
= 0.024. Median time to relapse was 8 months (DAC) versus 5 months (CON) for the entire groups and 6.5 months (DAC) versus 3.5 months (CON) for patients with active disease. In summary, our data indicated that the conditioning regimen containing low dose DAC may confer a survival advantage in high-risk AML patients with active disease undergoing allo-HSCT, and a prospective randomized trial is warranted to confirm these observations.</abstract><cop>London</cop><pub>Nature Publishing Group UK</pub><pmid>33637882</pmid><doi>10.1038/s41409-021-01238-5</doi><tpages>9</tpages><orcidid>https://orcid.org/0000-0003-1766-7891</orcidid></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0268-3369 |
| ispartof | Bone marrow transplantation (Basingstoke), 2021-07, Vol.56 (7), p.1674-1682 |
| issn | 0268-3369 1476-5365 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_2494304246 |
| source | MEDLINE; SpringerLink Journals; EZB-FREE-00999 freely available EZB journals |
| subjects | 5-aza-2'-deoxycytidine 692/699/1541/1990/283/1897 692/699/67/1990/283/1897 Acute myeloid leukemia Busulfan Cell Biology Conditioning Cyclophosphamide Decitabine Dosage and administration Graft vs Host Disease Hematology Hematopoietic Stem Cell Transplantation Hematopoietic stem cells Humans Internal Medicine Leukemia Leukemia, Myeloid, Acute - therapy Medicine Medicine & Public Health Myeloid leukemia Prospective Studies Public Health Retrospective Studies Risk Stem cell transplantation Stem Cells Survival Transplantation Transplantation Conditioning |
| title | Low-dose decitabine as part of a modified Bu-Cy conditioning regimen improves survival in AML patients with active disease undergoing allogeneic hematopoietic stem cell transplantation |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-07T23%3A59%3A39IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_proqu&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Low-dose%20decitabine%20as%20part%20of%20a%20modified%20Bu-Cy%20conditioning%20regimen%20improves%20survival%20in%20AML%20patients%20with%20active%20disease%20undergoing%20allogeneic%20hematopoietic%20stem%20cell%20transplantation&rft.jtitle=Bone%20marrow%20transplantation%20(Basingstoke)&rft.au=Tang,%20Xiaowen&rft.date=2021-07-01&rft.volume=56&rft.issue=7&rft.spage=1674&rft.epage=1682&rft.pages=1674-1682&rft.issn=0268-3369&rft.eissn=1476-5365&rft_id=info:doi/10.1038/s41409-021-01238-5&rft_dat=%3Cgale_proqu%3EA667741620%3C/gale_proqu%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2549012892&rft_id=info:pmid/33637882&rft_galeid=A667741620&rfr_iscdi=true |